2826-LB: Diabetes Status and Comorbidity Burden Shape GLP-1 Treatment Decision-Making

Introduction and Objective: Understanding how patients engage in GLP-1 treatment decisions is critical for optimizing obesity and T2D care. In this study, we examined how T2D status and comorbidity burden influence patient involvement in brand selection among GLP-1 users for weight loss. Methods: Data are from two Ipsos syndicated US studies conducted in Q4 2025, both including GLP-1 users across indications. For this analysis, we focused on those using GLP-1s for weight loss: (1) Ipsos Obesity & Cardiometabolic Therapy Monitor, an online medical chart review study of 613 GLP-1 users reported by primary care physicians, endocrinologists, cardiologists, gastroenterologists, and bariatricians; (2) Ipsos Obesity Consumer Monitor, an online survey among general population adults including 1,370 GLP-1 users. Both assessed patient involvement in treatment selection, stratified by comorbidity count and T2D status. Results: Both data sources demonstrated that patients with multiple comorbidities were less involved in treatment decisions. The patients with no comorbidities were most likely to specifically request their treatment (39% physician-reported - data source 1; 34% patient-reported - data source 2), dropping to 13% and 25% respectively among those with 4+ comorbidities. When T2D was among the reported comorbidities, patients were even less likely to request specific brands (physician-reported: 16% vs 25% non-T2D; patient-reported: 26% vs 30%). This aligns with attitudinal findings: more T2D patients agree that “obesity is a chronic disease” (70% vs 59% non-T2D) and that they “need help to manage weight” (75% vs 67%). Those with 4+ comorbidities were also more likely to agree with these statements (vs those with no comorbidities). Conclusion: In this study, comorbidity burden and T2D status notably influence patient involvement in GLP-1 treatment decisions, with complex patients more reliant on HCP guidance. These findings highlight the need for differentiated patient engagement strategies as GLP-1 indications expand. Disclosure M.S. Tan: None. A. Levent: None. R. Schmuecking: None.